140 likes | 169 Views
THE INTELLIGENT KNIFE. WHO WE ARE. JACOB VITKAUSKAS HEAD SURGEON, KINGS COLLEGE, LONDON. JESSICA DAWSON HEAD SCIENTIST, IMPERIAL COLLEGE LONDON. LUCY LOHRMANN CEO, WATERS CORP. ARISTIDIS SIRINAKIS CFO, WATERS CORP. LUCY SHEPHARD CMO, WATERS CORP. 1 OUT OF 3 WOMEN. 1 OUT OF 2 MEN.
E N D
WHO WE ARE JACOB VITKAUSKAS HEAD SURGEON, KINGS COLLEGE, LONDON JESSICA DAWSON HEAD SCIENTIST, IMPERIAL COLLEGE LONDON LUCY LOHRMANN CEO, WATERS CORP. ARISTIDIS SIRINAKIS CFO, WATERS CORP. LUCY SHEPHARD CMO, WATERS CORP.
1 OUT OF 3 WOMEN 1 OUT OF 2 MEN RISK DEVELOPING CANCER DURING THEIR LIFETIME
BREAST CANCER RECURRENCE • 1/8 WOMEN DEVELOP BREAST CANCER • 22.9 % OR 46,000 BREAST CANCER PATIENTS HAVE 1< OPERATION
THE TWO TECHNOLOGIES ELECTROSURGERY MASS SPECTROMETRY
CLINICAL TRIALS ALL 81 PATIENTS HAD TUMORS REMOVED WITH 100% ACCURACY
COMPARITIVE COSTS IKNIFE CT SCANNER CANCER RADIATION ACCELERATOR USD $380,000 USD $2,500,000 USD $4,000,000
MARKET SHARE 125 BILLION USD SPENT ON CANCER TREATMENT BY US GOVERNMENT in 2010
POTENTIAL SAVINGS 45.5 MILLION USD = X 4,000 USD 11,370 INPATIENT SURGERIES BY MEMORIAL SLOAN KETTERING CANCER CENTER IN 2013 SAVED PER TUMOR REMOVAL SURGERY WITH IKNIFE MEDIAN POTENTIAL SAVINGS
FEWER SURGERIES SHORTER INPATIENT STAYS MORE HOPE